Cyramza® (Ramucirumab)

Para consultar la información para prescribir completa de Cyramza® (Ramucirumab) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

Ramucirumab: Administration

Administer diluted ramucirumab infusion via infusion pump. Do not administer as an IV push or bolus.


The information contained in this letter may not completely match the current local labeling for RAMUCIRUMAB. Please see local labeling approved in your country.

Calculate and Prepare Ramucirumab for Administration

Prepare the infusion solution using aseptic technique to ensure the sterility of the prepared solution.1

Each vial of ramucirumab is intended for single use only.1

Inspect the contents of the vials for particulate matter and discoloration prior to dilution. If particulate matter or discolorations are identified, discard the vial.

Calculate the dose and the required volume of ramucirumab needed to prepare the infusion solution.

  • Vials contain either 100 mg or 500 mg as a 10-mg/mL solution of ramucirumab.

Dilute ramucirumab as required to achieve a final volume of 250 mL. Only use sterile sodium chloride (0.9%) solution for injection as a diluent.

  • In case of prefilled IV infusion container usage: based on the calculated volume of ramucirumab, remove the corresponding volume of sterile sodium chloride (0.9%) solution for injection from the prefilled 250-mL IV container. Aseptically transfer the calculated volume of ramucirumab to the IV container. The final total volume in the container should be 250 mL.
  • In case of empty IV infusion container usage: aseptically transfer the calculated volume of ramucirumab into an empty IV container. Add a sufficient quantity of sterile sodium chloride (0.9%) solution for injection to the container to make the total volume 250 mL.

The container should be gently inverted to ensure adequate mixing. Do not freeze or shake the infusion solution. Do not dilute with other solutions or co-infuse with other electrolytes or medication.

Parenteral drug products should be inspected visually for particulate matter prior to administration. If particulate matter is identified, discard the infusion solution.

Discard any unused portion of ramucirumab left in a vial, as the product contains no preservatives.1

Administration of Ramucirumab

Administer ramucirumab as an IV infusion only. Do not administer ramucirumab as an IV push or bolus.1

Administer diluted ramucirumab infusion via infusion pump over approximately 60 minutes. A separate infusion line must be used for the infusion and the line must be flushed with sterile sodium chloride (0.9%) solution for injection at the end of the infusion.1

In the United States, the ramucirumab prescribing information recommends that if the first 60-minute infusion of ramucirumab is tolerated, then all subsequent infusions may be administered over 30 minutes. This recommendation is currently only approved in the United States and applies to all recommended doses of ramucirumab and all approved indications.2


1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.


IV = intravenous

Fecha de la última revisión: 2019 M08 11

Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico:

Envíe su consulta

Escriba su consulta